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The lactate anion is currently emerging as an oncometabolite. Lactate, produced and
exported by glycolytic and glutaminolytic cells in tumors, can be recycled as an oxidative
fuel by oxidative tumors cells. Independently of hypoxia, it can also activate transcription
factor hypoxia-inducible factor-1 (HIF-1) in tumor and endothelial cells, promoting
angiogenesis. These protumoral activities of lactate depend on lactate uptake, a process
primarily facilitated by the inward, passive lactate-proton symporter monocarboxylate
transporter 1 (MCT1); the conversion of lactate and NAD+ to pyruvate, NADH and
H+ by lactate dehydrogenase-1 (LDH-1); and a competition between pyruvate and
α-ketoglutarate that inhibits prolylhydroxylases (PHDs). Endothelial cells do not primarily
use lactate as an oxidative fuel but, rather, as a signaling agent. In addition to HIF-1,
lactate can indeed activate transcription factor nuclear factor-κB (NF-κB) in these
cells, through a mechanism not only depending on PHD inhibition but also on NADH
alimenting NAD(P)H oxidases to generate reactive oxygen species (ROS). While NF-κB
activity in endothelial cells promotes angiogenesis, NF-κB activation in tumor cells is
known to stimulate tumor progression by conferring resistance to apoptosis, stemness,
pro-angiogenic and metastatic capabilities. In this study, we therefore tested whether
exogenous lactate could activate NF-κB in oxidative tumor cells equipped for lactate
signaling. We report that, precisely because they are oxidative, HeLa and SiHa human
tumor cells do not activate NF-κB in response to lactate. Indeed, while lactate-derived
pyruvate is well-known to inhibit PHDs in these cells, we found that NADH aliments
oxidative phosphorylation (OXPHOS) in mitochondria rather than NAD(P)H oxidases in
the cytosol. These data were confirmed using oxidative human Cal27 and MCF7 tumor
cells. This new information positions the malate-aspartate shuttle as a key player in the
oxidative metabolism of lactate: similar to glycolysis that aliments OXPHOS with pyruvate
produced by pyruvate kinase and NADH produced by glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), oxidative lactate metabolism aliments OXPHOS in oxidative
tumor cells with pyruvate and NADH produced by LDH1.
Keywords: cancer metabolism, mitochondria, lactate signaling, oxidative phosphorylation (OXPHOS), nuclear
factor-κB, malate-aspartate shuttle, NADH, NAD(P)H oxidases (Nox)
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INTRODUCTION
The lactate anion was recently identified as a tumor growth-
promoting factor. In solid tumors, lactate is produced by
different cell types that metabolically rely on anaerobic glycolysis
(Kennedy and Dewhirst, 2010), aerobic glycolysis (Whitaker-
Menezes et al., 2011; Dhup et al., 2012) or glutaminolysis
(Vander Heiden et al., 2009) for survival and proliferation. Once
produced, lactate is exported together with protons by passive
monocarboxylate transporters (MCTs), among which MCT4 is
particularly well adapted for lactic acid release (Dimmer et al.,
2000; Ullah et al., 2006). If proton release and extracellular
acidification have been well characterized to promote tumor
progression, several studies also correlated high levels of
lactate in clinical tumor specimen to tumor aggressiveness and
progression to themetastatic stage (Walenta andMueller-Klieser,
2004). One possible interpretation is that lactate levels merely
reflect glycolytic activities in tumors, owing to the fact that
a glycolytic metabolism offers several oncogenic advantages
to tumor cells (Porporato et al., 2011). However, it is also
now clearly established that the lactate anion itself directly
promotes tumor progression. Lactate can indeed serve as an
oxidative fuel, thereby supporting glycolytic-oxidative tumor cell
cooperation (Sonveaux et al., 2008; Mendoza-Juez et al., 2012;
Guillaumond et al., 2013; Kennedy et al., 2013) and fibroblasts-
tumor cells metabolic relationships (Whitaker-Menezes et al.,
2011). It can also act as a paracrine factor that activates lactate-
sensitive signaling pathways. Collectively, these activities of
lactate primarily depend on the expression and activity of the
inward lactate transporterMCT1 at the surface of responsive cells
that take up lactate.
In endothelial cells, lactate acts as a signaling agent that
activates nuclear factor-κB (NF-κB) independently of hypoxia
(Vegran et al., 2011, 2012). This signaling pathway of lactate
involves MCT1-facilitated lactate uptake, lactate oxidation to
pyruvate (the LDH-1/LDH-B reaction), and pyruvate-mediated
inhibition of prolylhydroxylases (PHDs). It initiates the serial
activation of inhibitor of NF-κB kinase β (IKK2/IKKβ),
phosphorylation and degradation of inhibitor of NF-κB α
(IκBα), and induction of the transcriptional activity of NF-
κB. Interestingly, NF-κB activation in endothelial cells also
mandatorily relies on the reductive arm of the LDH-1 reaction,
i.e., NAD+ reduction in NADH + H+ (Vegran et al., 2011). In
this complementary pathway, NADH fuels NAD(P)H oxidases
(Noxs) that produce reactive oxygen species (ROS) to further
inactivate IκBα. Thus, activation of both pyruvate-PHD and
NADH-Nox signaling accounts for lactate-induced NF-κB
activation in endothelial cells (Vegran et al., 2011). Lactate
thereby supports autocrine interleukin-8 (IL-8) signaling and
IL-8-induced tumor angiogenesis.
Active NF-κB is a dimer formed most often by the
association of p50/NF-κB1 (that binds to DNA and contains
a nuclear translocation domain) with p65/RelA (that contains
transactivation domains). In tumor cells, NF-κB activation
can result from mutations and aberrant kinase activities that
essentially phosphorylate p65 on Ser536 (human sequence)
to enhance p65 transcriptional activity (Viatour et al., 2005).
Active NF-κB confers tumorigenic traits, including resistance
to apoptosis and to therapy, stemness, and pro-angiogenic and
metastatic capabilities (Chaturvedi et al., 2011). Because tumors
accumulate high levels of lactate (Walenta and Mueller-Klieser,
2004) and lactate activates NF-κB in endothelial cells (Vegran
et al., 2011), this study was aimed to test whether lactate could
also activate NF-κB in tumor cells. We focused on oxidative
tumor cells that do express the inward lactate transporter MCT1
and take up lactate, whereas glycolytic tumor cells are resistant
to lactate signaling as they preferentially release lactate via
MCT4 (passive transport) (De Saedeleer et al., 2012). We report
that, precisely because of oxidative phosphorylation (OXPHOS),
oxidative tumor cells do not activate NF-κB in response to lactate.
MATERIALS AND METHODS
Cells and Reagents
HeLa human cervix adenocarcinoma cells (ATCC) were
routinely cultured in RPMI 1640 containing Glutamax (Life
Technologies catalogue #61870) supplemented with 10% FBS, 1%
penicillin/streptomycin, 1mM sodium pyruvate and 1X MEM
non-essential amino acids (Life Technologies); SiHa human
cervix squamous cell carcinoma cells and Cal27 human tongue
squamous cell carcinoma cells (ATCC) in DMEM containing 4.5
g/L glucose and Glutamax (Life Technologies catalogue #61965)
supplemented with 10% FBS and 1% penicillin/streptomycin;
MCF7 human breast adenocarcinoma cells (ATCC) in MEM
alpha supplemented with 10% FBS, 1% penicillin/streptomycin,
1mM sodium pyruvate and 0.1% insulin; and human vein
umbilical endothelial cells (HUVECs, Clonetics) in EBM2-MV
medium (Cambrex).Where indicated, cells in freshmediumwere
treated with human TNFα (Miltenyi), sodium L-lactate (Sigma),
N-acetyl-L-cysteine (NAC, Sigma), H2O2 (Sigma), rotenone
(Sigma) or diethyl pyrocarbonate (DEPC, Sigma). To avoid
modifications of extracellular pH, lactate was always used as
a sodium salt in pH-buffered media. All experiments were
performed in the presence of glucose.
Metabolic Assays
Oxygen consumption rates were determined on a Seahorse
XF96 bioenergetic analyzer according to manufacturer’s
recommendations. Twenty thousand cells per well were
plated 24-h before the experiment. NAD+/NADH ratios
were determined using the NAD/NADH-Glo Assay from
Promega according to manufacturer’s instructions. All data were
normalized for total protein content.
Western Blotting
After treatment, cells were washed once with ice-cold phosphate
buffer saline (PBS) and lysed on ice in RIPA buffer containing
protease and phosphatase inhibitors. Cell fractionation was
performed using the Nuclear Extract Kit from Active Motif
according to manufacturer’s instructions. Cell lysates were frozen
and thawed to ensure complete cell lysis and centrifuged
at 13,000 g for 10min, 4◦C. Supernatants were collected
and protein concentrations were determined using a Pierce
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BCA assay (Life Technologies). An equal amount of proteins
were transferred in tubes containing Laemmli sample buffer
(Sigma), heated for 5min at 95◦C, loaded in each well of
homemade 1.5mm-thick acrylamide gels, and separated by SDS-
PAGE. Following electrophoresis, gels were blotted on PVDF
membranes. After blocking for 1 h in TBST (10mM Tris-HCl
pH 8.0, 150mM NaCl, 0.5% Tween-20) containing 5% bovine
serum albumin (BSA), membranes were incubated with primary
antibodies for 1 h, washed, and incubated for 1 h with secondary
antibodies. Membranes were washed and incubated with ECL
(Thermo Scientific) for chemiluminescent protein detection
and quantification (ImageJ). Primary antibodies were rabbit
polyclonals against Nox1 (Abcam #ab55831), Nox2 (Abcam
#ab80508), Nox4 (Abcam #ab41886) and lamin A/C (Santa Cruz
#sc-20681); rabbit monoclonals against total p65 (Cell Signaling
#8242) and phospho-serine536-p65 (Cell Signaling #3033); and
a mouse monoclonal against IκBα (Cell Signaling #4814).
Secondary antibodies were a goat anti-rabbit (Jackson #111-035-
003) and a goat anti-mouse (Jackson #115-035-003) coupled to
horseradish peroxidase.
NF-κB Activity
NF-κB activity was measured using a luciferase reporter assay.
Twenty-four hours before treatments, cells were transfected
with pGL4.32 [luc2P/NF-κB-RE/Hygro], a Firefly luciferase-
expressing plasmid driven by an artificial promoter containing
five NF-κB consensus response elements and by pRL-Renilla-
luciferase (Promega, constitutive expression for transfection
normalization) using TransIT-2020 (Mirus Bio LLC). Reporter
assays were performed with the dual luciferase kit (DLR) from
Promega on a GloMax 96-well plate luminometer (Promega). All
data were normalized for transfection efficiency by pRL Renilla
luciferase.
ROS Measurement
Intracellular reactive oxygen species (ROS) were measured
using 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Sigma), as
previously reported (Vegran et al., 2011). Signals were detected
and quantified on a SpectraMax Imaging Cytometer i3. Data were
normalized for total cell number.
Statistics
All results are expressed as mean ± SEM. “N” refers to
the number of independent experiments and “n” to the total
number of replicates per treatment condition. Error bars are
sometimes smaller than symbols. Student’s t-test or One-way
ANOVA (Tukey’s or Bonferroni’s post-hoc test) were used
where convenient. P < 0.05 was considered to be statistically
significant.
RESULTS
Lactate does not Activate NF-κB in
Oxidative Tumor Cells
We selected SiHa and HeLa human cervix cancer cells as models:
both cell types have been well described to primarily rely on
an oxidative metabolism, to express MCT1 and to be sensitive
to lactate-induced PHD inhibition (inward lactate gradient)
(Sonveaux et al., 2008; De Saedeleer et al., 2012). Compared
to WiDr human colon cancer cells that are highly glycolytic
and resistant to lactate signaling (outward lactate gradient) (De
Saedeleer et al., 2012), we first found that SiHa and HeLa are
more oxidative than the human vein umbilical endothelial cells
(HUVECs) that initially served to identify the lactate to NF-
κB pathway (Vegran et al., 2011) (Figure 1A). HUVECs express
Nox2 and Nox4 (Van Buul et al., 2005), and SiHa and HeLa cells
did express Nox1, Nox2, and Nox4 (Figure 1B).
To test the effects of exogenous lactate on NF-κB activity,
we first analyzed p65 Ser536-phosphorylation/activation in HeLa
cells exposed to exogenous lactate. Lactate was used as a sodium
salt (to avoid lactate-independent pH responses) at a 10mM
concentration (to match with the average lactate concentration
found in human tumors) (Walenta and Mueller-Klieser, 2004),
i.e., conditions upon which lactate inhibits PHDs in these cells
(De Saedeleer et al., 2012). Time-course measurements over 1-
h showed no increase in the phospho-Ser536-p65/total p65 ratio
(Figure 1C), whereas TNFα used as a positive control did trigger
p65 Ser536-phosphorylation. Total p65 levels were unaffected
by lactate but decreased with TNFα treatment (Figure 1C).
In SiHa cells, similarly to what was observed in HeLa, time-
course measurements up to 6 h showed a stable phospho-
Ser536-p65/total p65 ratio (Figure 1D). TNFα increased p65
phosphorylation in these cells.
That exogenous lactate is unable to trigger NF-κB activity in
oxidative tumor cells was verified using a specific dual luciferase
reporter assay. Increasing doses of lactate were used, ranging
from 0 to 40mM, the latter corresponding to the highest dose
of lactate ever detected in human tumors (Walenta and Mueller-
Klieser, 2004). Up to 3 h after treatment, no significant changes of
NF-κB activity were detected in HeLa and SiHa cells (Figure 1E).
Still, TNFα induced a 10 to 40-fold increase in NF-κB activity in
these assays.
Oxidative Tumor Cells are Capable of
Activating NF-κB
In endothelial cells, lactate-induced NF-κB activation depends
on two signaling pathways that must be activated together,
with pyruvate and NADH as key intermediates (Vegran et al.,
2011). Previous data from our laboratory clearly evidenced that
lactate is efficiently converted to pyruvate in both HeLa and
SiHa cells (Sonveaux et al., 2008; De Saedeleer et al., 2012,
2014) and that pyruvate then inhibits PHDs in these cells (De
Saedeleer et al., 2012). Despite this, HeLa cells did not reduce
IκBα expression (Figure 2A) and did not translocate p65 to the
nucleus (Figure 2B) in response to lactate, whereas they did so in
response to TNFα.
Many tumor cells display constitutive NF-κB activity
(Chaturvedi et al., 2011), which could make them insensitive to
further induction by lactate. However, HeLa and SiHa cells were
highly sensitive to TNFα (Figures 1C–E, 2A,B). Because both
cell lines do express Nox isoforms (Figure 1B), we tested whether
high basal oxidative stress could account for constitutive NF-κB
activation. It was not the case as N-acetyl-L-cysteine (NAC,
Frontiers in Pharmacology | www.frontiersin.org 3 October 2015 | Volume 6 | Article 228
Van Hée et al. Lactate and NF-κB in tumor cells
FIGURE 1 | Exogenous lactate does not activate NF-κB in oxidative HeLa and SiHa tumor cells. (A) The basal, maximal and OXPHOS-dependent (i.e.,
rotenone and olygomycin-sensitive) oxygen consumption rates of SiHa, HeLa human tumor cells and human umbilical vein endothelial cells (HUVEC) were determined
using Seahorse bioanalysis (n ≥ 6). (B) Representative western blots showing Nox1, Nox2, Nox4 and β-actin expression in HeLa and SiHa cells. (C) HeLa cells were
treated with vehicle (control, C), 10mM of sodium L-lactate (lactate, L) or 20 ng/ml of TNFα (positive control) for the indicated periods of time. The phosphorylation of
p65 on serine 536 (p-Ser536-p65) and total p65 expression were detected using western blotting in the lysates of the cells. Treatment with TNFα (20 ng/ml) served as
positive control. A representative blot is shown, and the graph depicts p-Ser536-p65/total p65 used as a marker of NF-κB activity (N = 3; n = 9) (Viatour et al., 2005).
(D) As in (C) but using SiHa cells (N = 9; n = 9). (E) HeLa and SiHa cells were treated with vehicle (control), increasing doses of lactate or TNFα. NF-κB activity was
determined using a dual luciferase reporter assay (n = 4 all). All data represent means ± SEM. **P < 0.01, ***P < 0.005 vs. SiHa (A) or control (C–E); #P < 0.05,
###P < 0.005 vs. HeLa (A).
10mM) did not decrease the phospho-Ser536-p65/total p65 ratio
(Figure 2C). Conversely, exposure of the cells to 0.8mM H2O2
did increase p65 phosphorylation in both cell lines (Figure 2D).
In HeLa cells, H2O2 effects were maximal at 1-h, followed by
a rapid decline down to basal levels. In SiHa cells, significant
induction was detected from 1 to 6-h. In both cell lines, lactate
had no additive effects over H2O2 (Figure 2D). These data
collectively suggest that oxidative tumor cells are insensitive to
lactate-induced NF-κB activation because of a failure to trigger
NADH-Nox-ROS signaling.
Because OXPHOS Consumes Cytosolic
NADH, Oxidative HeLa Tumor Cells do not
Activate NF-κB in Response to Lactate
HeLa and SiHa cells efficiently convert lactate to pyruvate, which
implies the effective conversion of NAD+ to NADH + H+
by LDH-1 (Sonveaux et al., 2008; De Saedeleer et al., 2012,
2014). However, it does not obligatorily mean that NADH is
made available for Noxs. In agreement with an alternative use of
NADH, we found that treating HeLa and SiHa cells with 10mM
of lactate did not decrease the NAD+/NADH ratio (Figure 3A).
Frontiers in Pharmacology | www.frontiersin.org 4 October 2015 | Volume 6 | Article 228
Van Hée et al. Lactate and NF-κB in tumor cells
FIGURE 2 | Hydrogen peroxide activates NF-κB in oxidative tumor cells. (A) Inhibitor of NF-κB α (IκBα) was detected in the lysates of HeLa cells treated during
30min with vehicle (control), lactate (10mM) or TNFα (20 ng/ml). A representative western blot is shown and the graph depicts IκBα expression (N = 3; n = 9). (B) The
phosphorylation of p65 on serine 536 (p-Ser536-p65) and total p65 expression were detected using western blotting in the cytosolic (left panel, N = 3; n = 9) and
lamin A/C-positive nuclear (right panel, N = 3; n = 9) lysates of HeLa cells treated as in (A). Representative blot is shown, and the graph depicts p-Ser536-p65/total
p65 ratios. (C) HeLa (left panel, N = 3; n = 9) and SiHa (right panel, N = 3; n = 9) cells were treated for 20min with vehicle (control) or 10mM of N-acetyl-L-cysteine
(NAC), after which p-Ser536-p65 and total p65 were detected in cell lysates. Representative blots are shown, and graphs depict p-Ser536-p65/total p65 ratios. (D)
HeLa (left panel, N = 3; n = 9) and SiHa (right panel, N = 3; n = 9) cells were treated during increasing amounts of time with vehicle (control, C), H2O2 (0.8mM) or
H2O2 (0.8mM) and lactate (10mM). p-Ser536-p65 and total p65 were detected in cell lysates. Representative western blots are shown, and graphs depict
p-Ser536-p65/total p65 ratios. All data represent means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005, ns P > 0.05 vs. control.
This observation indicated that oxidative tumor cells use NADH
for another purpose than fueling Noxs.
Compared to endothelial cells that generate most of their
energy through glycolysis (Figure 1A and De Bock et al., 2013),
we reasoned that oxidative tumor cells would have highOXPHOS
avidity for NADH. NADH of cytosolic origin can indeed be
imported into mitochondria via the malate-aspartate shuttle to
fuel the electron transport chain (ETC), providing additional
proton motor force for ATP production (Ying, 2008). To
test whether LDH-1-derived NADH is preferentially used for
mitochondrial supply, we first treated the cells with rotenone
to fully inhibit ETC at complex I, where NADH is used.
In the absence of lactate, OXPHOS impairment significantly
decreased the NAD+/NADH ratio (Figure 3B), induced Ser536-
p65 phosphorylation (Figure 3C) and activated NF-κB in HeLa
cells. Rotenone also significantly decreased the NAD+/NADH
ratio in SiHa cells (Figure 3B), which was however not associated
to NF-κB induction (Figures 3C,D). Interestingly, in HeLa and
SiHa cells, TNFα triggered NF-κB much more efficiently than
rotenone (Figures 3C,D). While ROS are downstream effectors
of TNFα (Chu, 2013) and ROS activate NF-κB (Gloire et al.,
2006), full ETC inhibition by rotenone did not modify ROS
levels in the cells (Figure 3E) and NF-κB activation by rotenone
was ROS-independent as it could not be blocked by NAC
(Figure 3D). Supplying exogenous lactate to OXPHOS-impaired
cells did not further activate NF-κB (Figure 3D).
Because MCT1-mediated lactate uptake is a passive process
depending on the gradient of lactate across the plasmamembrane
and lactate must be converted to pyruvate to fuel the TCA cycle
and for intracellular signaling (Dhup et al., 2012), inhibiting
OXPHOS decreases lactate uptake by oxidative tumor cells
(Sonveaux et al., 2008). Therefore, we finally reasoned that
inhibiting the mitochondrial use of NADH could be sufficient
to restore the capacity of lactate to activate NF-κB. To this aim,
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FIGURE 3 | OXPHOS inhibition by rotenone activates NF-κB in oxidative HeLa tumor cells. (A) HeLa (left panel, N = 3; n = 9) and SiHa (right panel, N = 3;
n = 9) cells were treated for 30min with 10mM of lactate, and NAD+/NADH ratios were determined. (B–D) HeLa (left panels) and SiHa (right panels) cells were
treated for 30min with vehicle (control, C), 10mM of lactate (L), 2.5µM of rotenone (Rot.), 10mM of N-acetyl-L-cysteine (NAC), 20 ng/ml of TNFα or combinations
thereof. (B) NAD+/NADH ratios were determined (N = 3; n = 9 all). (C) p-Ser536-p65 and total p65 expression were detected using western blotting. Representative
blots are shown, and graphs depict p-Ser536-p65/total p65 ratios (N = 3; n = 9 all). (D) NF-κB activity was determined using a dual luciferase reporter assay (N = 3;
n = 12 all). (E) HeLa (left panel, N = 3; n = 12) and SiHa (right panel N = 3; n = 12) cells were treated for the indicated time periods with vehicle (control) or rotenone
(2.5µM), after which intracellular ROS levels were measured using the fluorescent probe DCFH-DA. All data represent means ± SEM. *P < 0.05, **P < 0.01,
***P < 0.005, ns P > 0.05 vs. control.
we used diethyl pyrocarbonate (DEPC) (Samartsev et al., 1997),
an inhibitor of the mitochondrial glutamate-aspartate antiporter
that composes the malate-aspartate shuttle indispensable for
the mitochondrial import of cytosolic NADH (Dionisi et al.,
1974; Greenhouse and Lehninger, 1977). In HeLa (Figure 4A)
and in SiHa cells (Figure 4B), DEPC (1mM) activated NF-
κB, which was repressed using NAC. It clearly indicated that
the mitochondrial use of NADH prevents ROS-dependent NF-
κB activation in these cells. Time-course experiments further
showed that exogenous lactate activated NF-κB in HeLa cells
upon inhibition of the malate-aspartate shuttle, as detected 3-
h after treatment (Figure 4A). Comparatively, we detected no
additional effect of lactate on DEPC-induced NF-κB activation
in SiHa cells (Figure 4B). These data were confirmed using
two additional tumor cell lines: Cal27 human tongue squamous
cell carcinoma cells and MCF7 human breast adenocarcinoma
cells. Cal27 cells were equally oxidative when compared
to HeLa (Figure 5A). They did express Nox1, Nox2, and
Nox4 (Figure 5B) but did not phosphorylate p65 on Ser536
(Figure 5C) and did not activate NF-κB (Figure 5D) in the
presence of exogenous lactate. Inhibition of the mitochondrial
glutamate-aspartate antiporter by DEPC increased P-Ser536-
p65 expression (Figure 5C) and NF-κB activity, with a further
activation of NF-κB by lactate detected 1 and 2 h after DEPC
treatment (Figure 5D). Comparatively, MCF7 cells were equally
oxidative when compared to SiHa (Figure 5E). As for all the
oxidative tumor cells tested in this study, they did express
Nox1, Nox2, and Nox4 (Figure 5F) but did not activate the
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FIGURE 4 | Inhibition of the malate-aspartate shuttle restores the ability of lactate to activate NF-κB in oxidative HeLa tumor cells. (A,B) NF-κB activity
was determined using a dual luciferase reporter assay. HeLa (A, N = 3; n = 12), SiHa (B, N = 3; n = 12) cells were treated for the indicated amounts of time with
vehicle (control), 10mM of lactate, 1mM of diethyl pyrocarbonate (DEPC, a pharmacological inhibitor of the mitochondrial glutamate-aspartate antiporter) (Samartsev
et al., 1997), 10mM of N-acetyl-L-cysteine (NAC) or combinations thereof. All data represent means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005, ns P > 0.05 vs.
control or as indicated.
NF-κB pathway in response to lactate (Figures 5G,H). DEPC
increased P-Ser536-p65 expression (Figure 5G) and NF-κB
activity (Figure 5H) with no additional effect of lactate 3 h after
DEPC treatment, thus recapitulating the behavior of SiHa cells.
DISCUSSION
Oncometabolite lactate is a tumor growth-promoting factor that
can be used as a metabolic fuel and as a signaling agent by various
cell types. Based on recent findings in endothelial cells (Vegran
et al., 2011, 2012), this study explored the possibility that lactate
would activate NF-κB in oxidative tumor cells. We report that,
despite the fact that it is oxidized to pyruvate (together with the
reduction of NAD+ to NADH + H+) (Lu et al., 2002, 2005;
Sonveaux et al., 2008; De Saedeleer et al., 2012), lactate does not
activate NF-κB in oxidative tumor cells.
With respect to lactate signaling in cancer, Lu et al. (2002,
2005) initially showed that lactate is a hypoxia mimetic capable
of activating transcription factor hypoxia-inducible factor-1
(HIF-1) in normoxic tumor cells. These authors reported
that lactate oxidation to pyruvate by LDH-1 supports a
competition between pyruvate and αKG that inhibits HIF
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FIGURE 5 | Inhibition of the malate-aspartate shuttle restores the ability of lactate to activate NF-κB in oxidative Cal27 tumor cells. (A) The basal,
maximal and OXPHOS-dependent oxygen consumption rates of HeLa and Cal27 human tumor cells were determined using Seahorse bioanalysis (n ≥ 6). (B)
Representative western blots showing Nox1, Nox2, Nox4 expression in Cal27 cells. (C) Cal27 cells were treated for the indicated amounts of time with vehicle
(control, C), 1mM of diethyl pyrocarbonate (DEPC, D), 10mM Lactate (L), the combination of DEPC and lactate (DL), or TNFα (20 ng/ml), after which p-Ser536-p65
and total p65 were detected in cell lysates. Representative western blots are shown. (D) Cal27 cells were treated as in (C) except that NF-κB activity was determined
using a dual luciferase reporter assay 1, 2, and 3 h after treatment (n = 4). (E) The basal, maximal and OXPHOS-dependent oxygen consumption rate of SiHa and
MCF7 human tumor cells were determined using Seahorse bioanalysis (n ≥ 6). (F) Representative western blots showing Nox1, Nox2, Nox4 expression in MCF7 cells.
(G) MCF7 cells were treated for 3 h with vehicle (control, C), 1mM of DEPC (D), 10mM of L-Lactate (L) or combination (DL), after which p-Ser536-p65, total p65 and
β-actin were detected in cell lysates. A 1-h treatment with TNFα was used as positive control. Representative western blots are shown. (H) Same as in (G) except that
NF-κB activity was determined using a dual luciferase reporter assay (n = 4). All data represent means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005, ns P > 0.05 vs.
control or as indicated.
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FIGURE 6 | Model showing that the oxidative use of NADH opposes NF-κB activation by lactate in oxidative tumor cells. In tumors, endothelial cells (top)
and oxidative tumor cells (bottom) take up lactate, a process facilitated by the passive lactate-proton symporter monocarboxylate transporter 1 (MCT1). Both cell
types convert lactate + NAD+ to pyruvate + NADH + H+ intracellularly (the lactate dehydrogenase B [LDHB] reaction). Pyruvate competes with α-ketoglutarate (αKG)
(Continued)
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FIGURE 6 | Continued
to inhibit prolylhydroxylases (PHDs), resulting e.g., in the stabilization of hypoxia-inducible factor-1 subunit α (HIF-1α) (Vegran et al., 2011; De Saedeleer et al., 2012;
Sonveaux et al., 2012). Endothelial cells do not use lactate-derived pyruvate and NADH as oxidative fuels (Sonveaux et al., 2012), thus further rendering NADH
available to fuel NAD(P)H oxidases (Noxs) (Vegran et al., 2011). Together with pyruvate-mediated PHD inhibition, the production of reactive oxygen species (ROS) by
Nox accounts for lactate-induced activation of nuclear factor-κB (NF-κB) in these cells. Comparatively, oxidative tumor cells use lactate (Sonveaux et al., 2008) and
NADH (this study) as oxidative fuels. It renders these cells insensitive to lactate-induced NF-κB activation. NADH influx in mitochondria is controlled by the
malate-aspartate shuttle gated by the oxoglutarate carrier (OGC, a malate-αKG exchanger) and by the glutamate-aspartate antiporter (GAA). Consequently, inhibiting
the malate-aspartate shuttle can restore the ability of lactate to activate NF-κB in oxidative tumor cells, as illustrated in this study with HeLa cells treated by GAA
inhibitor diethyl pyrocarbonate (DEPC). Other abbreviations: AST, aspartate aminotransferase; ETC, electron transport chain; IκBα, inhibitor and Cal27 of NF-κB α;
Ikkα/β, inhibitor of NF-κB kinase α/β; MDH, malate dehydrogenase; MPC, mitochondrial pyruvate carrier; OXPHOS, oxidative phosphorylation.
PHDs. Comparatively, because lactate uptake is a passive
process (facilitated by MCTs and driven by the gradient of
lactate across the plasma membrane), glycolytic tumor cells
that produce lactate from pyruvate do not activate HIF-1 in
response to exogenous lactate (De Saedeleer et al., 2012). PHDs
are iron-containing enzymes that use oxygen and αKG to
catalyze the hydroxylation of 2 proline residues in the oxygen-
dependent domain (ODD) of HIF-1 subunit α. While under
normoxia ODD proline hydroxylation normally targets HIF-1α
for polyubiquitylation and proteasome-mediated degradation,
Lu et al. elegantly showed that cell exposure to exogenous lactate
interferes with this pathway and accounts for normoxic HIF-
1 activation. Consequently, lactate induces the expression of
several HIF-1 target genes, among which vascular endothelial
growth factor A (VEGFA) in normoxic oxidative tumor cells
(Lu et al., 2005; De Saedeleer et al., 2012) and VEGF receptor-
2 (VEGFR2) in normoxic endothelial cells (Sonveaux et al., 2012)
and macrophages (Colegio et al., 2014) are key contributors to
lactate-induced angiogenesis. In response to lactate, endothelial
cells further increase their production of basic fibroblast
growth factor (bFGF) through a mechanism that indirectly
depends on HIF-1 (Sonveaux et al., 2012), and tumor-associated
macrophages are polarized to the M2 protumoral phenotype
(Colegio et al., 2014). Together, HIF-1 activation by lactate
was found to trigger angiogenesis in vivo (De Saedeleer et al.,
2012; Sonveaux et al., 2012), which for anticancer effects can be
blocked by MCT1 inhibitors and, conversely, can be exploited
therapeutically in wounds to accelerate the healing process
(Porporato et al., 2012; Chereddy et al., 2014, 2015).
NF-κB also contributes to lactate-induced angiogenesis in
tumors. Indeed, when, in addition to pyruvate inhibiting PHDs,
NADH aliments ROS production by Noxs, IκBα is ultimately
degraded, releasing p65 from its inhibitory interaction with
IκBα (Vegran et al., 2011). Thus, both pyruvate-mediated
inhibition of PHDs and NADH-mediated ROS generation by
Noxs are simultaneously and mandatorily required for lactate
to activate NF-κB in endothelial cells (Figure 6). Generally
speaking, endothelial cells have a glycolytic rate that can be as
high as glycolytic tumor cells (De Bock et al., 2013), which is in
frame with their function of delineating oxygen-delivering blood
vessels. Accordingly, we illustrate here that the HUVECs that
were instrumental to identify lactate-induced NF-κB activation
(Vegran et al., 2011) are much more glycolytic than SiHa and
HeLa tumor cells that served as oxidative archetypes to identify
lactate-induced HIF-1 activation (De Saedeleer et al., 2012).
Endothelial cells can use lactate to activate HIF-1 (Sonveaux et al.,
2012) and NF-κB (Vegran et al., 2011), but not as a major fuel
for cell survival in the absence of glucose (Sonveaux et al., 2012).
Comparatively, oxidative tumor cells can use lactate as a major
fuel (Sonveaux et al., 2008) and to activate HIF-1 (De Saedeleer
et al., 2012), but not to activate NF-κB (this study). Highly
glycolytic tumor cells do not use exogenous lactate as a fuel or as a
signaling agent because their abundant release of lactate opposes
lactate uptake (MCTs are passive transporters) (De Saedeleer
et al., 2012). At least in oxidative HeLa and Cal27 cells, the lack
of response of the NF-κB pathway to lactate can be explained by
a preferential use of NADH by OXPHOS in mitochondria rather
than to aliment Noxs: inhibition of the mitochondrial uptake of
NADH by DEPC restored NF-κB activation by lactate in these
cells (Figures 4, 5). While DEPC per se already activated NF-
κB in HeLa and Cal27 cells, lactate exerted an additional effect,
collectively indicating that it is indeed the cytosolic availability
of NADH that drives NF-κB activity in these models. Using
HeLa, we further evidenced that the activity of DEPC was ROS-
mediated as it could be blocked by NAC. Similarly, DEPC
activated NF-κB in SiHa and MCF7 cells. However, lactate did
not further activate the pathway, which we attribute to a better
efficacy and longer time of action of DEPC in these cells that are
twice more oxidative than HeLa and Cal27. Importantly, tumors
including those established in vivo with oxidative tumor cells
are heterogeneous metabolically (Sonveaux et al., 2008; Payen
et al., 2015). Compared to the archetypic oxidative cell lines
used in this study, microenvironmental influences on tumor
cell metabolism could thus generate a range of intermediate
metabolic phenotypes with different responsiveness of the NF-κB
pathway to lactate. It is also important to stress that TNFα can be
secreted locally in tumors essentially by macrophages, resulting
in a receptor-mediated activation of NF-κB that promotes
tumor growth during cancer-associated chronic inflammation
(for details, see reference Muntané, 2011).
Full ETC blockade by rotenone activated NF-κB
independently of ROS in HeLa cells, with no additional
effect of lactate. It failed to do so in SiHa cells. The lack of effect
of lactate can be explained by the fact that lactate uptake is
a passive process driven by the gradient of lactate across the
plasma membrane (Dhup et al., 2012; Halestrap and Wilson,
2012): following the mass action law and as demonstrated
experimentally (Sonveaux et al., 2008; De Saedeleer et al., 2012),
full ETC inhibition can inhibit lactate uptake and activity because
products of the LDH1 reaction are not consumed any more.
However, at this stage, we have no consistent explanation for
the effects of rotenone alone. A path to explore could be the
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capability of rotenone to trigger TNFα release and signaling, as
recently observed in microglial cells (Yuan et al., 2013).
Finally, we believe that the major finding of this study is
that, in oxidative tumor cells, both pyruvate (Sonveaux et al.,
2008) and NADH produced following lactate oxidation by LDH1
primarily serve to fuel mitochondrial metabolism (Figure 6).
This observation offers a striking similarity with the glycolytic
pathway that, when coupled to mitochondrial metabolism, fuels
the TCA cycle with pyruvate produced by pyruvate kinase, and
OXPHOS with NADH produced by glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). This finding positions the malate-
aspartate shuttle as a key contributor to the oxidative metabolism
of cancer cells and LDH1 as a potential target to simultaneously
inhibit lactate metabolism and signaling.
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